FORT LAUDERDALE, Fla--Preliminary data on the treatment of breast and
colorectal cancer patients at National Comprehensive Cancer Network (NCCN)
member institutions show that the members are in compliance with the network's
guidelines, Jane Weeks, MD, MSc, of the Dana-Farber Cancer Institute, said
at the second annual NCCN conference.
In addition to its cancer guidelines initiative (eight guidelines were
presented at last year's meeting and eight preliminary guidelines at this
year's conference), the NCCN has taken the first steps toward the creation
of a comprehensive, uniform, prospective outcomes database, Dr. Weeks said.
The data will be used to monitor adherence with guidelines at NCCN institutions
and will ultimately help define optimal strategies for managing common
Dr. Weeks described early results of two ongoing projects of the NCCN's
Outcomes Committee. These projects are laying important groundwork for
the outcomes effort. First, a tumor registry project is using existing
data to look at patterns of care within the network's member institutions
and comparing them to national benchmark data. Second, a pilot study is
underway that will prospectively collect data on key quality-based outcome
indicators in breast cancer patients at five NCCN institutions.
Care Surpasses National Norms
The tumor registry project collected data on the treatment of breast
and colorectal cancer patients submitted by nine member institutions during
1993, 1994, and 1995 to the National Cancer Data Bank (NCDB), a national
tumor registry compiled by the American College of Surgeons. These data
were then compared with national data published by the NCDB.
"We were gratified to see that the care being delivered in NCCN
institutions, at least in the areas we looked at, appeared to be close
to the levels that we would expect," Dr. Weeks told Oncology News
International. Also encouraging was the fact that the patterns of care
in those institutions were in compliance with the NCCN guidelines.
Specifically, these very preliminary data showed that a greater percentage
of patients with stage II breast cancer treated at NCCN institutions received
adjuvant chemotherapy, compared with the national data (90% versus 58%).
Similarly, the rate of breast-conserving surgery in patients with stage
I or II breast cancer was about 10% higher in NCCN institutions than in
the nation as a whole (52% versus 42%).
Likewise, the use of adjuvant chemotherapy in patients with stage II
or III colon cancer occurred at a much higher rate at NCCN institutions,
compared with national benchmark data.
The analysis further showed that, at NCCN institutions, the majority
of patients with rectal cancer underwent sphincter-sparing surgery. No
national data are available for comparison.
There are several drawbacks of the tumor registry project, Dr. Weeks
pointed out: The NCDB data are incomplete and are not collected uniformly
everywhere. Also, no information on such factors as comorbidity is included.
Breast Cancer Pilot Study
The prospective outcomes database that the NCCN is poised to amass will
not be subject to these drawbacks, she said. Ultimately, this project will
provide data on a wide variety of outcomes, such as response, recurrence,
survival, hospital days, employment status, days lost from work, and performance
The pilot study involves five NCCN institutions: City of Hope, Dana-Farber,
Fox Chase, M.D. Anderson, and Roswell Park. Together, these centers expect
to provide data on approximately 4,000 to 5,000 breast cancer cases per
Before accumulating those data, the NCCN institutions had to agree on
which data to collect. The result was the creation of the data dictionary--a
voluminous document that specifies exactly which data to collect and how
to define every variable. "The stakes are high," Dr. Weeks said,
"because once an undertaking of this magnitude is begun and data are
collected, it is exceedingly difficult to change the system."
The second task was to pilot test strategies for data collection and
analysis. The NCCN encouraged the five institutions involved in the pilot
study to use whatever data collection strategy was already in place at
their centers. However, the key was to make sure that those existing data
collection mechanisms could be modified in such a way as to lend themselves
to the contribution of data to a single database, she said.
The third and final phase, which is slated for completion in July, is
the actual collection of data on all breast cancer cases in the five centers.
In the future, similar outcomes data will be accumulated for other common